business news
Insiders at Copart and The Marcus Corporation Buy Shares While Masonite International Sees a Sale
By
Jonathan Moreland
Oct 01, 2013 9:55 am
Plus, there was a sale at Array Biopharma.
PRINT
Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside sales and purchases filed with the SEC on Monday, September 30, 2013.
Notable Purchases:
In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."
Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.
At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.
Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
Notable Purchases:
- Willis Johnson, Founder and Chairman of online auctions and vehicle remarketing services company Copart (NASDAQ:CPRT), bought 227,900 shares of company stock for $7,055,737.
- Philip Milstein, a director at movie theater, hotel, and resort company The Marcus Corporation (NYSE:MCS), bought 28,481 shares of company stock for $374,098.
- Centerbridge Credit GP Investors sold 1,012,500 shares of door designer and manufacturer Masonite International Corp (NYSE:DOOR) for $51,212,488.
- Liam Ratcliffe, a director at small molecule drug development company Array Biopharma (NASDAQ:ARRY), sold 1,125,728 shares of company stock for $6,749,722.
| #: | Filer Name | Insider Titles | Company Name | Ticker |
Trans Type |
Dollar Value |
|---|---|---|---|---|---|---|
|
1
|
CB,DIR,BO
|
B
|
$7,055,737
|
|||
|
2
|
CEO,DIR
|
B
|
$487,801
|
|||
|
3
|
DIR
|
JB*
|
$374,098
|
|||
|
4
|
O
|
B
|
$249,070
|
|||
|
5
|
DIR,BO
|
JB*
|
$200,000
|
|||
|
6
|
TT
|
B
|
$99,861
|
|||
|
7
|
DIR
|
JB*
|
$99,844
|
|||
|
8
|
DIR
|
B
|
$86,514
|
|||
|
9
|
DIR
|
B
|
$57,592
|
|||
|
10
|
DIR
|
JB*
|
$56,250
|
| #: | Filer Name | Insider Titles | Company Name | Ticker |
Trans Type |
Dollar Value |
|---|---|---|---|---|---|---|
|
1
|
BO
|
S
|
$51,212,488
|
|||
|
2
|
BO
|
S
|
$10,259,483
|
|||
|
3
|
DIR
|
S
|
$6,749,722
|
|||
|
4
|
BO
|
S
|
$4,530,427
|
|||
|
5
|
VP
|
S
|
$2,159,601
|
|||
|
6
|
BO
|
JS*
|
$1,950,000
|
|||
|
7
|
DIR
|
AS
|
$1,592,000
|
|||
|
8
|
VP
|
AS
|
$1,307,024
|
|||
|
9
|
VP
|
S
|
$1,274,164
|
|||
|
10
|
BO
|
AS
|
$1,116,978
|
Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes
An important note from Jonathan Moreland, founder of Insider Insights:In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."
Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.
At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.
Jonathan Moreland is also the author of "Profit From Legal Insider Trading."
No positions in stocks mentioned.
